Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
115
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 2.30 | 0.03% |
CAC 40 | 7,715.42 | 8.05 | -0.10% |
DAX 40 | 24,145.32 | 71.65 | 0.30% |
Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
FTSE 100 | 8,821.71 | 15.18 | 0.17% |
HKSE | 24,148.07 | 260.24 | 1.09% |
NASDAQ | 20,412.52 | 188.59 | -0.92% |
Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
S&P 500 | 6,229.98 | 49.37 | -0.79% |
S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
SSE Composite Index | 3,497.48 | 24.35 | 0.70% |